search
Back to results

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

Primary Purpose

Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Hypofractionated Radiation Therapy
Laboratory Biomarker Analysis
Quality-of-Life Assessment
Questionnaire Administration
Radiation Therapy
Sponsored by
M.D. Anderson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Invasive Breast Carcinoma focused on measuring Breast cancer, hypofractionation, radiation therapy, regional nodal irradiation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria, if receiving postoperative radiation therapy

  • Radiation oncologist recommends radiation treatment to the supraclavicular and infraclavicular fossa (i.e. RNI).
  • Pathologically-confirmed invasive breast cancer. If patients undergo upfront surgery, the pathologic stage must be T0-T3, N0-N2a or N3a. If patients receive neoadjuvant chemotherapy prior to surgery, the clinical stage must be T0-T3, N0-N2a or N3a. T4b disease is permitted if the patient undergoes breast conserving surgery.
  • Treatment with mastectomy or segmental mastectomy and axillary evaluation (sentinel node evaluation, axillary sampling, or axillary lymph node dissection). If the patient has T0 disease, breast surgery is not required.
  • Age 18 years or older.
  • If enrolling on in the arm lymphedema assessment cohort, documentation of arm volume measurement by perometer prior to axillary surgery.
  • If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration, and the patient must have no evidence of disease for this prior non-breast cancer.
  • Patients must be enrolled on the trial within 24 weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy. If after trial enrollment it is determined the patient requires additional cytotoxic chemotherapy or additional breast cancer surgery prior to radiation therapy the patient may stay on trial but the patient must start radiation therapy within 24 weeks of the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy.

Inclusion Criteria, if receiving preoperative radiation therapy

  • Surgeon and radiation oncologist recommend preoperative radiation therapy
  • Radiation oncologist recommends radiation treatment to the supraclavicular and infraclavicular fossa (i.e. RNI).
  • Pathologically-confirmed invasive breast cancer. The clinical stage must be T0-T3, N0-N3b
  • Planned treatment with mastectomy and axillary evaluation (sentinel node evaluation, axillary sampling, or axillary lymph node dissection).
  • Planned breast reconstruction with autologous reconstruction.
  • Age 18 years or older.
  • If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration, and the patient must have no evidence of disease for this prior non-breast cancer.

Exclusion Criteria, if receiving postoperative radiation therapy

  • Pathologic or clinical evidence for a stage T4 breast cancer. However, T4b disease is permitted if the patient undergoes breast conserving surgery.
  • Pathologic or clinical evidence for a stage N2b, N3b, or N3c breast cancer (supraclavicular, or internal mammary lymph node involvement).
  • Clinical or pathologic evidence for distant metastases.
  • Current diagnosis of invasive breast cancer in the contralateral breast (ductal carcinoma in situ is permitted).
  • Prior diagnosis of invasive breast cancer in the contralateral breast.
  • If enrolling on in the arm lymphedema assessment cohort, current diagnosis of bilateral breast cancer.
  • History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breast. Except those patients enrolled and treated on the PRECISE trial (MD Anderson 2017-0362).
  • Patient is pregnant.
  • Patients who are cognitively impaired. Subjects will undergo a brief physical exam including a brief exam to determine cognitive review.

Exclusion Criteria, if receiving preoperative radiation therapy

  • Pathologic or clinical evidence for a stage T4 breast cancer.
  • Pathologic or clinical evidence for a stage N3c breast cancer (supraclavicular lymph node involvement).
  • Clinical or pathologic evidence for distant metastases.
  • Current diagnosis of invasive breast cancer in the contralateral breast (ductal carcinoma in situ is permitted).
  • Prior diagnosis of invasive breast cancer in the contralateral breast.
  • History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breast. Except those patients enrolled and treated on the PRECISE trial (MD Anderson 2017-0362).
  • Patient is pregnant.
  • Patients who are cognitively impaired. Subjects will undergo a brief physical exam including a brief exam to determine cognitive review.

Sites / Locations

  • MD Anderson Cancer Center (Banner)Recruiting
  • Scripps- MD Anderson CancerRecruiting
  • MD Anderson Cancer Center (Banner)- Northern ColoradoRecruiting
  • Baptist - MD Anderson Cancer CenterRecruiting
  • Orlando Health Cancer Institute
  • Piedmont Healthcare
  • Community MD Anderson Cancer Center EastRecruiting
  • Community MD Anderson Cancer Center SouthRecruiting
  • Community MD Anderson Cancer Center NorthRecruiting
  • Cooper Hospital University Medical CenterRecruiting
  • Ohio HealthRecruiting
  • M D Anderson Cancer CenterRecruiting
  • UT Health San Antonio - MD Anderson Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Arm I: Hypofractionated Regional Nodal Irradiation (RNI)

Arm II: Standard Regional Nodal Irradiation (RNI)

Arm Description

Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.

Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.

Outcomes

Primary Outcome Measures

Lymphedema rate as assessed by perometry
Will compare between patients randomized to short versus standard regional nodal irradiation (RNI). Will use a two-sided chi-squared test with a significance level of 0.05.

Secondary Outcome Measures

Volume of affected and unaffected arm as assessed by perometry
The Shapiro-Wilk test will be used to objectively assess the normality of the data and these findings will be visually confirmed by inspecting normal probability quantile-quantile plots. If the data are not normally distributed, a normalizing transformation before using t-test or a non-parametric method such as the Wilcoxon rank sum test to compare the standardized difference between the two arms at each time point may be used.

Full Information

First Posted
September 19, 2016
Last Updated
September 18, 2023
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT02912312
Brief Title
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
Official Title
Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 23, 2017 (Actual)
Primary Completion Date
February 28, 2030 (Anticipated)
Study Completion Date
February 28, 2031 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied.
Detailed Description
Primary Objective: To compare the risk of locoregional recurrence, defined as a cancer recurrence in the ipsilateral breast, chest wall, or regional lymph nodes (axillary levels I-III, supraclavicular, or internal mammary) SECONDARY OBJECTIVES FOR BOTH COHORTS To compare the maximum standardized difference in arm volume between the affected arm and the unaffected arm within 24 months after completion of RNI between the two treatment arms. To compare maximal acute (within 6 weeks of treatment) and late (more than 6 weeks after treatment) skin and soft tissue toxicities using the NCI CTCAE v4.0 scale between patients assigned to short versus standard RNI. To compare patient-reported arm and shoulder function for the two treatment arms using the QuickDASH-9. To compare patient quality of life for the two treatment arms using EQ-5D-3L and PROMIS Fatigue SF 6a. To compare the peripheral blood cytokine profile at the end of radiation between patients assigned to short versus standard RNI. To evaluate the effect of the peripheral blood cytokine profile at the end of radiation on developing lymphedema. (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health) To evaluate the effect of homocysteine levels prior to radiation on developing lymphedema. (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health) To evaluate time to distant metastasis, disease-free survival and overall survival for patients assigned to short versus standard RNI. To evaluate the effect of lipid profiles prior to radiation on acute toxicity, patient reported outcomes, and the time to locoregional recurrence. (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health) To evaluate if DNA repair capacity contributes to the presence of acute radiation related toxicity and patient-reported quality of life decrements including fatigue and arm and shoulder symptoms. (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health) To evaluate changes in echocardiography global longitudinal strain measurements and cardiac serum biomarkers, based on measurements performed before and after RT, in patients assigned to short versus standard RNI. (optional procedure for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health) In a separate cohort of 50 patients who will receive RNI before surgery, to collect information on number of patients developing lymphedema within 24 months of RNI on reconstructive complications, and on patient reported quality of life, in those assigned to short versus standard RNI. Participating Cancer Network Sites, or Orlando Health, are not participating in this cohort. To evaluate patient-reported financial burdens using the Economic Strain and Resilience in Cancer- Financial Well- Being instrument. To determine whether radiation therapy induces de novo detectable clonal hematopoiesis mutations or alters the genetic landscape of existing clonal hematopoiesis mutations (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health). To determine whether radiation therapy or chemotherapy among individuals with pre- and/or post-treatment clonal hematopoiesis mutations is associated with adverse treatment effects and worse oncologic outcomes (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks. ARM II: Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks. In both arms, patients undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI. PATIENT EVALUATION: Patients participating in the trial will have their arm measured prior to radiation, during the final week of radiation and when they return for follow up visits. Patients will be checked for any arm swelling that may develop. Patients will also fill out questionnaires before treatment and when they return for follow up visits. Patients return 3 and 6 months after radiation, then every 6 months through two and a half years after radiation and then on a yearly basis until ten and a half years after finishing radiation. At some of the follow up visits, we measure arm volume and ask participants to complete questionnaires.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Keywords
Breast cancer, hypofractionation, radiation therapy, regional nodal irradiation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
985 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm I: Hypofractionated Regional Nodal Irradiation (RNI)
Arm Type
Experimental
Arm Description
Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
Arm Title
Arm II: Standard Regional Nodal Irradiation (RNI)
Arm Type
Active Comparator
Arm Description
Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
Intervention Type
Radiation
Intervention Name(s)
Hypofractionated Radiation Therapy
Other Intervention Name(s)
Hypofractionated Radiotherapy, hypofractionation
Intervention Description
Undergo hypofractionated RNI
Intervention Type
Other
Intervention Name(s)
Laboratory Biomarker Analysis
Intervention Description
Correlative studies
Intervention Type
Other
Intervention Name(s)
Quality-of-Life Assessment
Other Intervention Name(s)
Quality of Life Assessment
Intervention Description
Ancillary studies
Intervention Type
Other
Intervention Name(s)
Questionnaire Administration
Intervention Description
Ancillary studies
Intervention Type
Radiation
Intervention Name(s)
Radiation Therapy
Other Intervention Name(s)
Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
Intervention Description
Undergo standard RNI
Primary Outcome Measure Information:
Title
Lymphedema rate as assessed by perometry
Description
Will compare between patients randomized to short versus standard regional nodal irradiation (RNI). Will use a two-sided chi-squared test with a significance level of 0.05.
Time Frame
Up to 24 months
Secondary Outcome Measure Information:
Title
Volume of affected and unaffected arm as assessed by perometry
Description
The Shapiro-Wilk test will be used to objectively assess the normality of the data and these findings will be visually confirmed by inspecting normal probability quantile-quantile plots. If the data are not normally distributed, a normalizing transformation before using t-test or a non-parametric method such as the Wilcoxon rank sum test to compare the standardized difference between the two arms at each time point may be used.
Time Frame
Up to 126 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria, if receiving postoperative radiation therapy Radiation oncologist recommends radiation treatment to the supraclavicular and infraclavicular fossa (i.e. RNI). Pathologically-confirmed invasive breast cancer. If patients undergo upfront surgery, the pathologic stage must be T0-T3, N0-N2a or N3a. If patients receive neoadjuvant chemotherapy prior to surgery, the clinical stage must be T0-T3, N0-N2a or N3a. T4b disease is permitted if the patient undergoes breast conserving surgery. Treatment with mastectomy or segmental mastectomy and axillary evaluation (sentinel node evaluation, axillary sampling, or axillary lymph node dissection). If the patient has T0 disease, breast surgery is not required. Age 18 years or older. If enrolling on in the arm lymphedema assessment cohort, documentation of arm volume measurement by perometer prior to axillary surgery. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration, and the patient must have no evidence of disease for this prior non-breast cancer. Patients must be enrolled on the trial within 24 weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy. If after trial enrollment it is determined the patient requires additional cytotoxic chemotherapy or additional breast cancer surgery prior to radiation therapy the patient may stay on trial but the patient must start radiation therapy within 24 weeks of the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy. Inclusion Criteria, if receiving preoperative radiation therapy Surgeon and radiation oncologist recommend preoperative radiation therapy Radiation oncologist recommends radiation treatment to the supraclavicular and infraclavicular fossa (i.e. RNI). Pathologically-confirmed invasive breast cancer. The clinical stage must be T0-T3, N0-N3b Planned treatment with mastectomy and axillary evaluation (sentinel node evaluation, axillary sampling, or axillary lymph node dissection). Planned breast reconstruction with autologous reconstruction. Age 18 years or older. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration, and the patient must have no evidence of disease for this prior non-breast cancer. Exclusion Criteria, if receiving postoperative radiation therapy Pathologic or clinical evidence for a stage T4 breast cancer. However, T4b disease is permitted if the patient undergoes breast conserving surgery. Pathologic or clinical evidence for a stage N2b, N3b, or N3c breast cancer (supraclavicular, or internal mammary lymph node involvement). Clinical or pathologic evidence for distant metastases. Current diagnosis of invasive breast cancer in the contralateral breast (ductal carcinoma in situ is permitted). Prior diagnosis of invasive breast cancer in the contralateral breast. If enrolling on in the arm lymphedema assessment cohort, current diagnosis of bilateral breast cancer. History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breast. Except those patients enrolled and treated on the PRECISE trial (MD Anderson 2017-0362). Patient is pregnant. Patients who are cognitively impaired. Subjects will undergo a brief physical exam including a brief exam to determine cognitive review. Exclusion Criteria, if receiving preoperative radiation therapy Pathologic or clinical evidence for a stage T4 breast cancer. Pathologic or clinical evidence for a stage N3c breast cancer (supraclavicular lymph node involvement). Clinical or pathologic evidence for distant metastases. Current diagnosis of invasive breast cancer in the contralateral breast (ductal carcinoma in situ is permitted). Prior diagnosis of invasive breast cancer in the contralateral breast. History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breast. Except those patients enrolled and treated on the PRECISE trial (MD Anderson 2017-0362). Patient is pregnant. Patients who are cognitively impaired. Subjects will undergo a brief physical exam including a brief exam to determine cognitive review.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Karen Hoffman, MD
Phone
713-563-2331
Email
khoffman1@mdanderson.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen Hoffman, MD
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
MD Anderson Cancer Center (Banner)
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emily Grade, MD
Phone
480-256-6444
Email
Emily.Grade@bannerhealth.com
First Name & Middle Initial & Last Name & Degree
Emily Grade, MD
Facility Name
Scripps- MD Anderson Cancer
City
San Diego
State/Province
California
ZIP/Postal Code
92121
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ray Lin, MD
Phone
858-554-8788
Email
lin.ray@scrippshealth.org
First Name & Middle Initial & Last Name & Degree
Ray Lin, MD
Facility Name
MD Anderson Cancer Center (Banner)- Northern Colorado
City
Greeley
State/Province
Colorado
ZIP/Postal Code
80631
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Supriya Jain, MD
Phone
970-810-3894
Email
supriya.jain@bannerhealth.com
First Name & Middle Initial & Last Name & Degree
Supriya Jain, MD
Facility Name
Baptist - MD Anderson Cancer Center
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cynthia Anderson, MD
Phone
855-635-2667
Email
cynthia.anderson@bmcjax.com
First Name & Middle Initial & Last Name & Degree
Cynthia Anderson, MD
Facility Name
Orlando Health Cancer Institute
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cameron Swanick, MD
Phone
321-841-8650
Email
Cameron.Swanick@orlandohealth.com
First Name & Middle Initial & Last Name & Degree
Cameron Swanick, MD
Facility Name
Piedmont Healthcare
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30309
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adam Nowlan, MD
Phone
404-425-7900
Email
adam.nowlan@piedmont.org
First Name & Middle Initial & Last Name & Degree
Adam Nowlan, MD
Facility Name
Community MD Anderson Cancer Center East
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Weed, M D
Phone
317-621-7771
Email
dweed@ecommunity.com
First Name & Middle Initial & Last Name & Degree
Daniel Weed, M D
Facility Name
Community MD Anderson Cancer Center South
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46227
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Weed, M D
Phone
317-621-7771
Email
dweed@ecommunity.com
First Name & Middle Initial & Last Name & Degree
Daniel Weed, M D
Facility Name
Community MD Anderson Cancer Center North
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
49625
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Weed, M D
Phone
317-621-7771
Email
dweed@ecommunity.com
First Name & Middle Initial & Last Name & Degree
Daniel Weed, M D
Facility Name
Cooper Hospital University Medical Center
City
Camden
State/Province
New Jersey
ZIP/Postal Code
08103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stuti Ahlawat, MD
Phone
855-632-2667
Email
ahlawat-stuti@CooperHealth.edu
First Name & Middle Initial & Last Name & Degree
Stuti Ahlawat, MD
Facility Name
Ohio Health
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Virginia Davolitsis, MD
Phone
614-566-1250
Email
virginia.diavolitsis@ohiohealth.com
First Name & Middle Initial & Last Name & Degree
Virginia Davolitsis, MD
Facility Name
M D Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karen E. Hoffman, MD
Phone
713-563-2331
First Name & Middle Initial & Last Name & Degree
Karen E. Hoffman, MD
Facility Name
UT Health San Antonio - MD Anderson Cancer Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dalwadi Shraddha, M D
Phone
210-450-1000
Email
dalwadis@uthscsc.edu
First Name & Middle Initial & Last Name & Degree
Dalwadi Shraddha, M D

12. IPD Sharing Statement

Links:
URL
http://www.mdanderson.org
Description
MD Anderson Cancer Center

Learn more about this trial

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

We'll reach out to this number within 24 hrs